Treatment of the chronic hepatitis C complicated by mixed cryoglobulinemia with direct-acting antiviral agents

Treatment of the chronic hepatitis C complicated by mixed cryoglobulinemia with direct-acting antiviral agents

The aim of the study was to evaluate clinical, immunologic and anti-viral efficacy of antiviral therapy (АVT) with drugs of the direct antiviral action (DAA) of the chronic hepatitis C (CHC) complicated with secondary mixed cryoglobulinemia in small cohort of patients. Patients and methods: The coho...

Full description

Bibliographic Details
Main Authors:	N. V. Dunaeva, E. Yu. Kolpashchikova, S. Yu. Romanova, S. N. Kizhlo, S. V. Lapin, D. A. Gusev
Format:	Article
Language:	Russian
Published:	Journal Infectology 2018-12-01
Series:	Журнал инфектологии
Subjects:	криоглобулинемия криокрит внепечёночные проявления гепатит с терапия
Online Access:	https://journal.niidi.ru/jofin/article/view/804

Similar Items

Analysis of mortality and risk of death in HCV- and HCV/HIV-infected patients with extrahepatic manifestations
by: N. V. Dunaeva, et al.
Published: (2022-07-01)

Cryoglobulinemia and hepatitis C virus
by: N. V. Dunaeva, et al.
Published: (2014-09-01)

Antiviral therapy of chronic hepatitis C complicated by systemic cryoglobulinemic vasculitis
by: N. V. Dunaeva, et al.
Published: (2016-07-01)

Case-term Adverse Outcomes of Chronic Hepatitis C, Extrahepatic Manifestations of a Young Man Infected in Early Childhood
by: S. V. Baramzina, et al.
Published: (2015-12-01)

ВНЕПЕЧЕНОЧНЫЕ ПРОЯВЛЕНИЯ ХРОНИЧЕСКОГО ВИРУСНОГО ГЕПАТИТА С: КЛИНИЧЕСКОЕ НАБЛЮДЕНИЕ
by: Ксения Алексеевна Вютрих, et al.
Published: (2022-11-01)

Hepatitis E, to the 40th anniversary of the discovery of the virus by academician of the RAMS M.S. Balayan
by: M. I. Mikhailov, et al.
Published: (2021-10-01)

Cardiovascular aspects of HBV-infection
by: T. V. Antonova, et al.
Published: (2014-09-01)

Cryoglobulinemia and cryoglobulinemic vasculitis: etiological aspects and pathophysiological associations
by: I. Yu. Golovach, et al.
Published: (2020-03-01)

The modern options of chronic hepatitis C antiviral therapy with daclatasvir: results of named patient program
by: V. T. Ivashkin, et al.
Published: (2018-08-01)

Efficiency of Antiviral Therapy for Recurrence of Chronic Hepatitis C in Patients Undergoing Liver Transplantation
by: A. A. Sukhoruk, et al.
Published: (2014-09-01)

Iron metabolism in chronic hepatitis C patients on antiviral treatment
by: K. V. Zhdanov, et al.
Published: (2014-09-01)

Successful antiviral therapy for chronic hepatitis C in a patient after surgery for hepatocellular carcinoma (a clinical observation)
by: I. G. Nikitin, et al.
Published: (2018-08-01)

Real-world effectiveness and safety of pan-genotypic antiviral therapy for chronic HCV-infection: data from three clinical centers in St. Petersburg
by: D. A. Gusev, et al.
Published: (2023-01-01)

Eradication of hepatitits C virus in patient with cryoglobulinemic vasculitis and mutations D168E, L31V
by: N. V. Dunaeva, et al.
Published: (2020-03-01)

Effectiveness of combined antyviral therapy in children with chronic hepatitis C
by: G. P. Martynova, et al.
Published: (2014-09-01)

Change of the indices of the cytokine status in patients with chronic combined hepatitis B+C in a process of antiviral therapy
by: O. L. Sobolevskaya
Published: (2014-09-01)

Leukopenia and neutropenia in chronic hepatitis C patients with various underlying combination antiviral therapy
by: K. V. Zhdanov, et al.
Published: (2014-09-01)

Clinical significance blood platelet count in patients with chronic hepatitis C on the background of the various options combined antiviral therapy
by: K. V. Zhdanov, et al.
Published: (2014-09-01)

Clinical significance of anaemia in chronic hepatitis c on the combined antiviral therapy with pegylated
by: K. V. Zhdanov, et al.
Published: (2014-09-01)

Effectiveness and safety of narlaprevir in real clinical practice of chronic hepatitis C
by: V. V. Basina, et al.
Published: (2019-12-01)

Health-related quality of life in patients with chronic hepatitis C during combined antiviral therapy
by: V. L. Rozina, et al.
Published: (2019-12-01)

Efficacy and safety of triple therapy with recombinant interleukin-1β, recombinant interferon-α and ribavirin in patients with chronic hepatitis C, genotype 1 infection, the non-responders to previous treatment with interferon and ribavirin
by: Yu. V. Lobzin, et al.
Published: (2014-09-01)

IMPACT OF THE ANTIVIRAL THERAPY ON CARDIAC HEMODYNAMICS IN PATIENTS WITH CHRONIC VIRAL HEPATITIS
by: M. V. Chistyakova, et al.
Published: (2015-09-01)

CLINICAL MANIFESTATIONS AND TREATMENT EFFICIENCY OF THOSE SUFFERING FROM TB/HIV CO -INFECTION AND HEPATITIS
by: T. Yu. SАLINА, et al.
Published: (2017-10-01)

Betaleukin in therapy of chronic hepatitis C
by: E. S. Romanova, et al.
Published: (2014-10-01)

Antiviral therapy in chronic hepatitis C (G1) in Russia: cost and effectiveness
by: A. V. Rudakova, et al.
Published: (2015-04-01)

ETIOTROPIC THERAPY OF VIRAL HEPATITIS
by: S. B. Chuelov, et al.
Published: (2017-09-01)

Treatment of hepatitis C in liver transplant recipients in the Moscow Center for Liver Transplantation within 10 years
by: M. Sh. Khubutia, et al.
Published: (2016-01-01)

Efficacy of antiviral therapy in the treatment of severe forms of acute hepatitis B
by: E. V. Esaulenko, et al.
Published: (2016-02-01)

The efficacy and safety of double (cepeginterferon alfa-2b and ribavirin) and triple (simeprevir, cepeginterferon alfa 2b and ribavirin) treatment regimens in chronic hepatitis C patients. The experience of everyday clinical practice
by: N. P. Blokhina, et al.
Published: (2016-07-01)

Clinical and laboratory characteristics of occult hepatitis B
by: E. V. Esaulenko, et al.
Published: (2016-04-01)

Гепатити та вагітність (огляд літератури)
by: H. I. Ishchenko, et al.
Published: (2019-12-01)

Differentiated approach at the choice of chronic hepatitis C antiviral therapy mode (real clinical practice experience)
by: I. Yu. Pirogova, et al.
Published: (2018-08-01)

Characteristics of Hepatitis C Epidemic Process in the Republic of Belarus
by: V. S. Vysotskaya, et al.
Published: (2021-01-01)

Efficacy and safety of сepeginterferon alfa-2b in double treatment regimen (cepeginterferon alfa-2b and ribavirin) of antiviral therapy in patients with chronic hepatitis C genotypes 2 and 3. Experience of real clinical practice
by: A. I. Pavlov, et al.
Published: (2016-11-01)

Efficacy and safety of the Russian protease inhibitor narlaprevir at treatment-naive and earlier treated noncirrhotic patients with the 1st genotype chronic hepatitis C (PIONEER study)
by: M. V. Mayevskaya, et al.
Published: (2018-08-01)

Chronic erosive seropositive arthritis in a patient with chronic hepatitis C
by: L P Ananjeva, et al.
Published: (2008-02-01)

Features of the course and therapy of HIV infection in children at different stages of the disease
by: J. C. Hakizmana, et al.
Published: (2020-06-01)

Cost-effectiveness of antiviral therapy in chronic hepatitis C (G1)
by: A. V. Rudakova, et al.
Published: (2016-02-01)

Automation of pharmacoeconomic evaluation of the rationality of prescribing and its today’s relevance
by: D V Pavlov, et al.
Published: (2014-12-01)